Free Shipping on All Orders $75 Or More!

Your Trusted Brand for Over 35 Years

Health Protocols

Multiple Sclerosis


  1. SOLAR trial. Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). 11/28/2016.
  2. Noseworthy, J. H., et al. "Multiple Sclerosis." N Engl J Med 343.13 (2000): 938-52.
  3. Dutta, R., and B. D. Trapp. "Pathogenesis of Axonal and Neuronal Damage in Multiple Sclerosis." Neurology 68.22 Suppl 3 (2007): S22-31; discussion S43-54.
  4. Trapp, B. D., et al. "Axonal Transection in the Lesions of Multiple Sclerosis." N Engl J Med 338.5 (1998): 278-85.
  5. Bjartmar, C., et al. "Neurological Disability Correlates with Spinal Cord Axonal Loss and Reduced N-Acetyl Aspartate in Chronic Multiple Sclerosis Patients." Ann Neurol 48.6 (2000): 893-901.
  6. Lovas, G., et al. "Axonal Changes in Chronic Demyelinated Cervical Spinal Cord Plaques." Brain 123 ( Pt 2) (2000): 308-17.
  7. Smith, E. J., W. F. Blakemore, and W. I. McDonald. "Central Remyelination Restores Secure Conduction." Nature 280.5721 (1979): 395-6.
  8. Compston, A., and A. Coles. "Multiple Sclerosis." Lancet 359.9313 (2002): 1221-31.
  9. Friese, M. A., et al. "The Value of Animal Models for Drug Development in Multiple Sclerosis." Brain 129.Pt 8 (2006): 1940-52.
  10. Goverman, J. "Autoimmune T Cell Responses in the Central Nervous System." Nat Rev Immunol 9.6 (2009): 393-407.
  11. El-Behi, M., et al. "The Encephalitogenicity of T(H)17 Cells Is Dependent on Il-1- and Il-23-Induced Production of the Cytokine Gm-Csf." Nat Immunol (2011).
  12. Goldberg P. Multiple Sclerosis: vitamin D and calcium as environmental determinants of prevalence (a viewpoint). Part 1: sunlight, dietary factors and epidemiology. Intern J Environ Stud 1974, 6: 19-27.
  13. Craelius W. comparative epidemiology of multiple sclerosis and dental caries. J Epidemiol Community Health. 1978 Sep;32(3):155-65.
  14. Tremlett H et al. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology. 2008;31(4):271-9.
  15. Simpson S Jr. et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol. 2010 Aug;68(2):193-203.
  16. Correale J et al. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain. 2009 May;132(Pt 5):1146-60.
  17. Burton JM et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology. 2010 Jun 8;74(23):1852-9.
  18. Munger, K. L., et al. "Vitamin D Intake and Incidence of Multiple Sclerosis." Neurology 62.1 (2004): 60-5.
  19. Holick, M. F. "The Vitamin D Epidemic and Its Health Consequences." J Nutr 135.11 (2005): 2739S-48S.
  20. Merlino, L. A., et al. "Vitamin D Intake Is Inversely Associated with Rheumatoid Arthritis: Results from the Iowa Women's Health Study." Arthritis Rheum 50.1 (2004): 72-7.
  21. Ponsonby, A. L., A. McMichael, and I. van der Mei. "Ultraviolet Radiation and Autoimmune Disease: Insights from Epidemiological Research." Toxicology 181-182 (2002): 71-8.
  22. Ponsonby, A. L., R. M. Lucas, and I. A. van der Mei. "Uvr, Vitamin D and Three Autoimmune Diseases--Multiple Sclerosis, Type 1 Diabetes, Rheumatoid Arthritis." PhotochemPhotobiol 81.6 (2005): 1267-75.
  23. Dyment, D. A., G. C. Ebers, and A. D. Sadovnick. "Genetics of Multiple Sclerosis." Lancet Neurol 3.2 (2004): 104-10.
  24. Ebers, G. C., et al. "A Full Genome Search in Multiple Sclerosis." Nat Genet 13.4 (1996): 472-6.
  25. Sawcer, S., et al. "A Genome Screen in Multiple Sclerosis Reveals Susceptibility Loci on Chromosome 6p21 and 17q22." Nat Genet 13.4 (1996): 464-8.
  26. Zhang, Z., et al. "Two Genes Encoding Immune-Regulatory Molecules (Lag3 and Il7r) Confer Susceptibility to Multiple Sclerosis." Genes Immun 6.2 (2005): 145-52.
  27. Gregory, S. G., et al. "Interleukin 7 Receptor Alpha Chain (Il7r) Shows Allelic and Functional Association with Multiple Sclerosis." Nat Genet 39.9 (2007): 1083-91.
  28. Ramagopalan, S. V., et al. "Genomewide Study of Multiple Sclerosis." N Engl J Med 357.21 (2007): 2199-200; author reply 200-1.
  29. Orbach H, Agmon-Levin N, Zandman-Goddard G. Vaccines and autoimmune diseases of the adult. Discov Med. 2010 Feb;9(45):90-7.
  30. Fujinami RS, Oldstone MB, Wroblewska Z, et al. Molecular mimicry in virus infection: crossreaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments. Proc Natl Acad Sci U. S. A. 80.8 (1983): 2346-50.
  31. Zabriskie JB. Rheumatic fever: a model for the pathological consequences of microbial-host mimicry. Clin Exp Rheumatol. 1986;4(1):65-73.
  32. Ascherio, A., and K. L. Munger. "Environmental Risk Factors for Multiple Sclerosis. Part I: The Role of Infection." Ann Neurol 61.4 (2007): 288-99.
  33. Lünemann JD, Edwards N, Muraro PA, et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain. 2006 Jun;129(Pt 6):1493-506.
  34. Gelfand JM, Cree BA, McElroy J, Oksenberg J, Green R, MowryEM, Miller JW, Hauser SL, Green AJ. Neurology. Vitamin D in African Americans with multiple sclerosis.2011 May 24;76(21):1824-30.
  35. Pozzilli, C., et al. "Mri in Multiple Sclerosis During the Menstrual Cycle: Relationship with Sex Hormone Patterns." Neurology 53.3 (1999): 622-4.
  36. Hughes, M. D. "Multiple Sclerosis and Pregnancy." NeurolClin 22.4 (2004): 757-69.
  37. Sicotte, N. L., et al. "Treatment of Multiple Sclerosis with the Pregnancy Hormone Estriol." Ann Neurol 52.4 (2002): 421-8.
  38. El-Etr, M., et al. "Steroid Hormones in Multiple Sclerosis." J NeurolSci 233.1-2 (2005): 49-54.
  39. Soldan, S. S., et al. "Immune Modulation in Multiple Sclerosis Patients Treated with the Pregnancy Hormone Estriol." J Immunol 171.11 (2003): 6267-74.
  40. Bebo, B. F., Jr., et al. "Gonadal Hormones Influence the Immune Response to Plp 139-151 and the Clinical Course of Relapsing Experimental Autoimmune Encephalomyelitis." J Neuroimmunol 84.2 (1998): 122-30.
  41. Dalal, M., S. Kim, and R. R. Voskuhl. "Testosterone Therapy Ameliorates Experimental Autoimmune Encephalomyelitis and Induces a T Helper 2 Bias in the Autoantigen-Specific T Lymphocyte Response." J Immunol 159.1 (1997): 3-6.
  42. Bansil, S., et al. "Correlation between Sex Hormones and Magnetic Resonance Imaging Lesions in Multiple Sclerosis." ActaNeurolScand 99.2 (1999): 91-4.
  43. Tomassini V, Onesti E, Mainero C, et al. Sex hormones modulate brain damage in multiple sclerosis: MRI evidence. J NeurolNeurosurg Psychiatry. 2005 Feb;76(2):272-5.
  44. Landtblom, A. M., et al. "Organic Solvents and Multiple Sclerosis: A Synthesis of the Current Evidence." Epidemiology 7.4 (1996): 429-33.
  45. Riise, T., B. E. Moen, and K. R. Kyvik. "Organic Solvents and the Risk of Multiple Sclerosis." Epidemiology 13.6 (2002): 718-20.
  46. Rodrigo L, Hernández-Lahoz C, Fuentes D, et. al. Prevalence of celiac disease in multiple sclerosis.BMC Neurol. 2011 Mar 7;11:31.
  47. Shor DB, Barzilai O, Ram M Gluten sensitivity in multiple sclerosis: experimental myth or clinical truth? Ann N Y Acad Sci. 2009 Sep;1173:343-9.
  48. Kidd, P. M. "Multiple Sclerosis, an Autoimmune Inflammatory Disease: Prospects for Its Integrative Management." Altern Med Rev 6.6 (2001): 540-66.
  49. Guggenmos J, Schubart AS, et al. Antibody cross-reactivity between myelin oligodendrocyte glycoprotein and the milk protein butyrophilin in multiple sclerosis. J Immunol . 2004 Jan 1;172(1):661-8.
  50. Stefferl A, Schubart A, et al. Butyrophilin, a milk protein, modulates the encephalitogenic T cell response to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis. J Immunol. 2000 Sep 1;165(5):2859-65.
  51. Klawiter EC, Piccio L, Lyons JA, Mikesell R, O'Connor KC, Cross AH. Elevated intrathecal myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis. Arch Neurol. 2010 Sep;67(9):1102-8.
  52. Handel, A. E., et al. "Smoking and Multiple Sclerosis: An Updated Meta-Analysis." PLoS One 6.1 (2011): e16149.
  53. Hedstrom, A. K., et al. "Smoking and Two Human Leukocyte Antigen Genes Interact to Increase the Risk for Multiple Sclerosis." Brain 134.Pt 3 (2011): 653-64.
  54. Hernan, M. A., et al. "Cigarette Smoking and the Progression of Multiple Sclerosis." Brain 128.Pt 6 (2005): 1461-5.
  55. Riise, T., M. W. Nortvedt, and A. Ascherio. "Smoking Is a Risk Factor for Multiple Sclerosis." Neurology 61.8 (2003): 1122-4.
  56. Hartung, H. P., A. Bar-Or, and Y. Zoukos. "What Do We Know About the Mechanism of Action of Disease-Modifying Treatments in Ms?" J Neurol 251 Suppl 5 (2004): v12-v29.
  57. Rao, S. M., et al. "Cognitive Dysfunction in Multiple Sclerosis. I. Frequency, Patterns, and Prediction." Neurology 41.5 (1991): 685-91.
  58. Miller, D., et al. "Clinically Isolated Syndromes Suggestive of Multiple Sclerosis, Part I: Natural History, Pathogenesis, Diagnosis, and Prognosis." Lancet Neurol 4.5 (2005a): 281-8.
  59. Virley, D. J. "Developing Therapeutics for the Treatment of Multiple Sclerosis." NeuroRx 2.4 (2005): 638-49.
  60. Yu, M., et al. "Interferon-Beta Inhibits Progression of Relapsing-Remitting Experimental Autoimmune Encephalomyelitis." J Neuroimmunol 64.1 (1996): 91-100.
  61. Heine, S., et al. "Effects of Interferon-Beta on Oligodendroglial Cells." J Neuroimmunol 177.1-2 (2006): 173-80.
  62. Paty, D. W., and D. K. Li. "Interferon Beta-Lb Is Effective in Relapsing-Remitting Multiple Sclerosis. Ii. Mri Analysis Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. 1993 [Classical Article]." Neurology 57.12 Suppl 5 (2001): S10-5.
  63. Ziemssen T, Schrempf  W. "Glatiramer acetate: mechanisms of action in multiple sclerosis." Int Rev Neurobiol. 79 (2007): 537-70.
  64. Sela, M., and D. Teitelbaum. "Glatiramer Acetate in the Treatment of Multiple Sclerosis." Expert OpinPharmacother 2.7 (2001): 1149-65.
  65. Fox, E. J. "Management of Worsening Multiple Sclerosis with Mitoxantrone: A Review." ClinTher 28.4 (2006): 461-74.
  66. Ransohoff, R. M. "Natalizumab and Pml." Nat Neurosci 8.10 (2005): 1275.
  67. Warnke C, Menge T, Hartung H-P, et al. "Natalizumab and Progressive Multifocal Leukoencephalopathy." Arch Neurol. 2010;67(8):923-930.
  68. Center Watch. Newly Approved Drug Therapies: Ampyra. Available at: Accessed May 27, 2011.
  69. Nicholas R et al. Development of oral immunomodulatory agents in the management of multiple sclerosis. Drug Des DevelTher. 2011;5:255-74.
  70. Holmoy T and Celius EG. [Development of new therapies for multiple sclerosis.] Tidsskr Nor Laegeforen. 2011 mai 06;131(8):832-836.
  71. Schilling S, Goelz S, Linker R, et al. "Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration." Clin Exp Immunol. 145.1 (2006): 101-7.
  72. Shinto, L., et al. "The Perceived Benefit and Satisfaction from Conventional and Complementary and Alternative Medicine (Cam) in People with Multiple Sclerosis." Complement Ther Med 13.4 (2005): 264-72.
  73. Smolders, J., et al. "Vitamin D as an Immune Modulator in Multiple Sclerosis, a Review." J Neuroimmunol 194.1-2 (2008): 7-17.
  74. Wingerchuk DM et al. A pilot study of oral calcitriol (1,25-dihydroxyvitaminD3) for relapsing-remitting multiple sclerosis. J NeurolNeurosurg Psychiatry. 2005 Sep;76(9):1294-6.
  75. Kimball SM. Safety of vitamin D3 in adults with multiple sclerosis. Am J ClinNutr 2007; 86:645-51
  76. Gallai, V., et al. "Cytokine Secretion and Eicosanoid Production in the Peripheral Blood Mononuclear Cells of Ms Patients Undergoing Dietary Supplementation with N-3 Polyunsaturated Fatty Acids." J Neuroimmunol 56.2 (1995): 143-53.
  77. Bates, D., et al. "A Double-Blind Controlled Trial of Long Chain N-3 Polyunsaturated Fatty Acids in the Treatment of Multiple Sclerosis." J NeurolNeurosurg Psychiatry 52.1 (1989): 18-22.
  78. Shinto, L., et al. "Omega-3 Fatty Acid Supplementation Decreases Matrix Metalloproteinase-9 Production in Relapsing-Remitting Multiple Sclerosis." Prostaglandins LeukotEssent Fatty Acids 80.2-3 (2009): 131-6.
  79. Weinstock-Guttman, B., et al. "Low Fat Dietary Intervention with Omega-3 Fatty Acid Supplementation in Multiple Sclerosis Patients." Prostaglandins LeukotEssent Fatty Acids 73.5 (2005): 397-404.
  80. Horrobin, D. F. "Essential Fatty Acids in the Management of Impaired Nerve Function in Diabetes." Diabetes 46 Suppl 2 (1997): S90-3.
  81. Harbige, L. S., and M. K. Sharief. "Polyunsaturated Fatty Acids in the Pathogenesis and Treatment of Multiple Sclerosis." Br J Nutr 98 Suppl 1 (2007): S46-53.
  82. Bates, D., et al. "Trail of Polyunsaturated Fatty Acids in Non-Relapsing Multiple Sclerosis." Br Med J 2.6092 (1977): 932-3.
  83. Paty, D. W., et al. "Linoleic Acid in Multiple Sclerosis: Failure to Show Any Therapeutic Benefit." ActaNeurolScand 58.1 (1978): 53-8.
  84. Dworkin, R. H., et al. "Linoleic Acid and Multiple Sclerosis: A Reanalysis of Three Double-Blind Trials." Neurology 34.11 (1984): 1441-5.
  85. Mai, J., P. S. Sorensen, and J. C. Hansen. "High Dose Antioxidant Supplementation to Ms Patients. Effects on Glutathione Peroxidase, Clinical Safety, and Absorption of Selenium." Biol Trace Elem Res 24.2 (1990): 109-17.
  86. van Meeteren, M. E., et al. "Antioxidants and Polyunsaturated Fatty Acids in Multiple Sclerosis." Eur J ClinNutr 59.12 (2005): 1347-61.
  87. Hadzovic-Dzuvo A et al. Serum total antioxidant capacity in patients with multiple sclerosis. Bosn J Basic Med Sci. 2011 Feb;11(1):33-6.
  88. Arfsten, D., et al. "Impact of 30-Day Oral Dosing with N-Acetyl-L-Cysteine on Sprague-Dawley Rat Physiology." Int J Toxicol 23.4 (2004): 239-47.
  89. Singh, I., et al. "Cytokine-Mediated Induction of Ceramide Production Is Redox-Sensitive. Implications to Proinflammatory Cytokine-Mediated Apoptosis in Demyelinating Diseases." J BiolChem 273.32 (1998): 20354-62.
  90. Gilgun-Sherki, Y., et al. "Analysis of Gene Expression in Mog-Induced Experimental Autoimmune Encephalomyelitis after Treatment with a Novel Brain-Penetrating Antioxidant." J MolNeurosci 27.1 (2005): 125-35.
  91. Ortiz GG, Macías-Islas MA, Pacheco-Moisés FP, et al. Oxidative stress is increased in serum from Mexican patients with relapsing-remitting multiple sclerosis. Dis Markers. 2009;26(1):35-9.
  92. Miller E, Mrowicka M, Zołyński K, Kedziora J. Oxidative stress in multiple sclerosis.2009Dec;27(162):499-502.
  93. Biernacki, K., et al. "Regulation of Cellular and Molecular Trafficking across Human Brain Endothelial Cells by Th1- and Th2-Polarized Lymphocytes." J NeuropatholExpNeurol 63.3 (2004): 223-32.
  94. Cournu-Rebeix, I., et al. "Intercellular Adhesion Molecule-1: A Protective Haplotype against Multiple Sclerosis." Genes Immun 4.7 (2003): 518-23.
  95. Dedrick, R. L., S. Bodary, and M. R. Garovoy. "Adhesion Molecules as Therapeutic Targets for Autoimmune Diseases and Transplant Rejection." Expert OpinBiolTher 3.1 (2003): 85-95.
  96. Marracci, G. H., et al. "Alpha Lipoic Acid Inhibits T Cell Migration into the Spinal Cord and Suppresses and Treats Experimental Autoimmune Encephalomyelitis." J Neuroimmunol 131.1-2 (2002): 104-14.
  97. Morini, M., et al. "Alpha-Lipoic Acid Is Effective in Prevention and Treatment of Experimental Autoimmune Encephalomyelitis." J Neuroimmunol 148.1-2 (2004): 146-53.
  98. Schreibelt, G., et al. "Lipoic Acid Affects Cellular Migration into the Central Nervous System and Stabilizes Blood-Brain Barrier Integrity." J Immunol 177.4 (2006): 2630-7.
  99. Yadav, V., et al. "Lipoic Acid in Multiple Sclerosis: A Pilot Study." MultScler 11.2 (2005): 159-65.
  100. Bonakdar, R. A., and E. Guarneri. "Coenzyme Q10." Am Fam Physician 72.6 (2005): 1065-70.
  101. Siemieniuk, E., and E. Skrzydlewska. "[Coenzyme Q10: Its Biosynthesis and Biological Significance in Animal Organisms and in Humans]." PostepyHig Med Dosw (Online) 59 (2005): 150-9.
  102. Syburra, C., and S. Passi. "Oxidative Stress in Patients with Multiple Sclerosis." UkrBiokhimZh 71.3 (1999): 112-5.
  103. Spindler M, Beal MF, Henchcliffe C. Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatr Dis Treat. 2009;5:597-610. Epub 2009 Nov 16.
  104. Reynolds, E. H. "Multiple Sclerosis and Vitamin B12 Metabolism." J Neuroimmunol 40.2-3 (1992): 225-30.
  105. Miller, A., et al. "Vitamin B12, Demyelination, Remyelination and Repair in Multiple Sclerosis." J NeurolSci 233.1-2 (2005b): 93-7.
  106. Wade, D. T., et al. "A Randomised Placebo Controlled Exploratory Study of Vitamin B-12, Lofepramine, and L-Phenylalanine (The "CariLoder Regime") in the Treatment of Multiple Sclerosis." J NeurolNeurosurg Psychiatry 73.3 (2002): 246-9.
  107. Birks, J., and J. Grimley Evans. "Ginkgo Biloba for Cognitive Impairment and Dementia." Cochrane Database SystRev.2 (2007): CD003120.
  108. Birks, J., and J. Grimley Evans. "Ginkgo Biloba for Cognitive Impairment and Dementia." Cochrane Database SystRev.1 (2009): CD003120.
  109. Lovera, J., et al. "Ginkgo Biloba for the Improvement of Cognitive Performance in Multiple Sclerosis: A Randomized, Placebo-Controlled Trial." MultScler 13.3 (2007): 376-85.
  110. Aktas, O., et al. "Green Tea Epigallocatechin-3-Gallate Mediates T Cellular Nf-Kappa B Inhibition and Exerts Neuroprotection in Autoimmune Encephalomyelitis." J Immunol 173.9 (2004): 5794-800.
  111. Wong CP, Nguyen LP, Noh SK, Bray TM, Bruno RS, Ho E. Induction of regulatory T cells by green tea polyphenol EGCG. ImmunolLett. 2011 May 20. [Epub ahead of print]
  112. Abe, Y., S. Hashimoto, and T. Horie. "Curcumin Inhibition of Inflammatory Cytokine Production by Human Peripheral Blood Monocytes and Alveolar Macrophages." Pharmacol Res 39.1 (1999): 41-7.
  113. Natarajan, C., and J. J. Bright. "Curcumin Inhibits Experimental Allergic Encephalomyelitis by Blocking Il-12 Signaling through Janus Kinase-Stat Pathway in T Lymphocytes." J Immunol 168.12 (2002): 6506-13.
  114. Xie, L., et al. "Amelioration of Experimental Autoimmune Encephalomyelitis by Curcumin Treatment through Inhibition of Il-17 Production." IntImmunopharmacol 9.5 (2009): 575-81.
  115. Shirani A, Okuda DT, Stuve O. Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis. Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics.Jan 2016;13(1):58-69.
  116. Sedel F, Papeix C, Bellanger A, et al. High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Multiple sclerosis and related disorders. Mar 2015;4(2):159-169.
  117. Elston MS, Sehgal S, Du Toit S, Yarndley T, Conaglen JV. Factitious Graves' Disease Due to Biotin Immunoassay Interference-A Case and Review of the Literature. The Journal of clinical endocrinology and metabolism.Sep 2016;101(9):3251-3255.
  118. Sedel F, Bernard D, Mock DM, Tourbah A. Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis. Neuropharmacology. Nov 2016;110(Pt B):644-653.
  119. Tabarki B, Al-Shafi S, Al-Shahwan S, et al. Biotin-responsive basal ganglia disease revisited: clinical, radiologic, and genetic findings. Neurology.Jan 15 2013;80(3):261-267.
  120. Alfadhel M, Almuntashri M, Jadah RH, et al. Biotin-responsive basal ganglia disease should be renamed biotin-thiamine-responsive basal ganglia disease: a retrospective review of the clinical, radiological and molecular findings of 18 new cases. Orphanet journal of rare diseases. Jun 06 2013;8:83.
  121. Tourbah A, Lebrun-Frenay C, Edan G, et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Multiple sclerosis (Houndmills, Basingstoke, England). Nov 2016;22(13):1719-1731.
  122. Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C. Cerebrospinal fluid levels of biotin in various neurological disorders. Acta neurologica Scandinavica.Jun 1999;99(6):387-392.
  123. Heidker RM, Emerson MR, LeVine SM. Intersections of pathways involving biotin and iron relative to therapeutic mechanisms for progressive multiple sclerosis. Discovery medicine.Dec 2016;22(123):381-387.
  124. Peyro Saint Paul L, Debruyne D, Bernard D, Mock DM, Defer GL. Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis. Expert opinion on drug metabolism & toxicology.2016;12(3):327-344.
  125. Barbesino G. Misdiagnosis of Graves' Disease with Apparent Severe Hyperthyroidism in a Patient Taking Biotin Megadoses. Thyroid: official journal of the American Thyroid Association.Jun 2016;26(6):860-863.
  126. Minkovsky A, Lee MN, Dowlatshahi M, et al. High-dose biotin treatment for secondary progressive multiple sclerosis may interfere with thyroid assays. AACE clinical case reports.Fall 2016;2(4):e370-e373.
  127. Swank, R. L. "Multiple Sclerosis; a Correlation of Its Incidence with Dietary Fat." Am J Med Sci 220.4 (1950): 421-30.
  128. Swank, R. L., and B. B. Dugan. "Effect of Low Saturated Fat Diet in Early and Late Cases of Multiple Sclerosis." Lancet 336.8706 (1990): 37-9.
  129. Sicotte, N. L., et al. "Testosterone Treatment in Multiple Sclerosis: A Pilot Study." Arch Neurol 64.5 (2007): 683-8.
  130. Gold, S. M., et al. "Immune Modulation and Increased Neurotrophic Factor Production in Multiple Sclerosis Patients Treated with Testosterone." J Neuroinflammation 5 (2008): 32.
  131. El-Etr M, Ghoumari A, Sitruk-Ware R, Schumacher M. Hormonal influences in multiple sclerosis: new therapeutic benefits for steroids. Maturitas. 2011 Jan;68(1):47-51. Epub 2010 Oct 29.